Active Biotech (Sweden) Performance
| ACTI Stock | SEK 0.27 0.02 8.00% |
Active Biotech holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -0.65, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Active Biotech are expected to decrease at a much lower rate. During the bear market, Active Biotech is likely to outperform the market. Use Active Biotech total risk alpha, treynor ratio, value at risk, as well as the relationship between the sortino ratio and maximum drawdown , to analyze future returns on Active Biotech.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Active Biotech AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Active Biotech unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 26.2 M | |
| Free Cash Flow | -46.2 M |
Active |
Active Biotech Relative Risk vs. Return Landscape
If you would invest 44.00 in Active Biotech AB on September 1, 2024 and sell it today you would lose (17.00) from holding Active Biotech AB or give up 38.64% of portfolio value over 90 days. Active Biotech AB is generating 1.5073% of daily returns and assumes 26.8284% volatility on return distribution over the 90 days horizon. Simply put, majority of traded equity instruments are less risky than Active on the basis of their historical return distribution, and most equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Active Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Active Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Active Biotech AB, and traders can use it to determine the average amount a Active Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0562
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ACTI | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 26.83 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.51 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Active Biotech is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Active Biotech by adding it to a well-diversified portfolio.
Active Biotech Fundamentals Growth
Active Stock prices reflect investors' perceptions of the future prospects and financial health of Active Biotech, and Active Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Active Stock performance.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 224.92 M | |||
| Shares Outstanding | 264.89 M | |||
| Price To Earning | (8.47) X | |||
| Price To Book | 5.63 X | |||
| Price To Sales | 29.72 X | |||
| EBITDA | (48.52 M) | |||
| Cash And Equivalents | 53.13 M | |||
| Cash Per Share | 0.11 X | |||
| Total Debt | 200 K | |||
| Debt To Equity | 268.10 % | |||
| Book Value Per Share | 0.13 X | |||
| Cash Flow From Operations | (46.17 M) | |||
| Earnings Per Share | (0.25) X | |||
| Total Asset | 56.8 M | |||
| Current Asset | 65 M | |||
| Current Liabilities | 29 M | |||
About Active Biotech Performance
Assessing Active Biotech's fundamental ratios provides investors with valuable insights into Active Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Active Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Active Biotech AB , a biotechnology company, develops drugs for the treatment of neurodegenerative diseases, autoimmunityinflammatory, and cancer. Active Biotech AB was incorporated in 1982 and is based in Lund, Sweden. Active Biotech operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 12 people.Things to note about Active Biotech AB performance evaluation
Checking the ongoing alerts about Active Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Active Biotech AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Active Biotech AB is way too risky over 90 days horizon | |
| Active Biotech AB has some characteristics of a very speculative penny stock | |
| Active Biotech AB appears to be risky and price may revert if volatility continues | |
| Active Biotech AB has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| Net Loss for the year was (49.83 M) with profit before overhead, payroll, taxes, and interest of 6.72 M. | |
| Active Biotech AB has accumulated about 53.13 M in cash with (46.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.11. | |
| Roughly 46.0% of the company shares are held by company insiders |
- Analyzing Active Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Active Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Active Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Active Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Active Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Active Biotech's stock. These opinions can provide insight into Active Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Active Stock Analysis
When running Active Biotech's price analysis, check to measure Active Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Active Biotech is operating at the current time. Most of Active Biotech's value examination focuses on studying past and present price action to predict the probability of Active Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Active Biotech's price. Additionally, you may evaluate how the addition of Active Biotech to your portfolios can decrease your overall portfolio volatility.